The prognosis and survival prolongation effect of pirfenidone treatment

Pirfenidone is an anti-fibrotic drug used to treat mild to moderate idiopathic pulmonary fibrosis (IPF). As one of the oral anti-fibrotic drugs currently widely used in clinical practice, its mechanism of action is mainly multi-target, mainly by inhibiting the expression of pro-fibrotic factors such as TGF-β and TNF-α, thereby delaying the continued fibrosis process of the lung interstitium.

As for its improvement in prognosis and prolongation of survival after treatment, although many clinical studies at home and abroad have been conducted and published, in Baidu hot searches and patients’ search habits, “How long can pirfenidone prolong life?” and “Can taking Asrex control pulmonary fibrosis” have become the focus of attention.

Although each patient has individual differences in response to treatment, the overall trend shows that long-term and standardized use of pirfenidone can indeed significantly delay the decline of lung function, especially the prolongation of the stable time of FVC (vital capacity), which has become an important indicator for judging prognosis. Some studies indicate that pirfenidone users experienced significantly lower lung function declines over a one-year period than a group of patients who did not receive antifibrotic treatment.

Although this drug is not a cure, its "delaying the progression of the disease" effect itself is of great significance to improving the quality of life. At the same time, combined with oxygen therapy and rehabilitation training, the stable period of symptoms can be maintained longer. Especially for patients with early intervention, their overall survival is expected to be extended. In addition, some guidelines and expert consensus point out that long-term use of pirfenidone in individual patients may delay the onset of respiratory failure and reduce the frequency of acute exacerbations, thereby indirectly improving prognosis.

The current international treatment strategy for IPF has gradually shifted from "symptomatic relief" to "disease course control". As one of the core drugs, pirfenidone's prognostic management value under this strategy has become increasingly prominent. Therefore, for patients who hope to prolong their survival through drugs, pirfenidone is not only a necessary choice, but also requires early intervention and consistent treatment in order to obtain the maximum therapeutic benefit.

Reference materials:https://www.esbriet.com/